FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2493505337> ?p ?o ?g. }

• W2493505337 endingPage "56642" @default.
• W2493505337 startingPage "56628" @default.
• W2493505337 abstract "// Ruifang Liu 1, 2, 3 , Can Liu 2 , Dingxiao Zhang 2, 3, * , Bigang Liu 2 , Xin Chen 2, 3, * , Kiera Rycaj 2, 3, * , Collene Jeter 2 , Tammy Calhoun-Davis 2 , Yandong Li 1 , Tao Yang 1 , Junchen Wang 1 , Dean G. Tang 1, 2, 3, 4 1 Cancer Stem Cell Institute, Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China 2 Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park, Smithville, TX 78957, USA 3 Department of Pharmacology & Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA 4 Centers for Cancer Epigenetics, Stem Cell and Developmental Biology, RNA Interference and Non-coding RNAs, and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA * These authors have contributed equally to this work Correspondence to: Ruifang Liu, email: ruifang02.liu@gmail.com Dean G. Tang, email: Dean.Tang@Roswellpark.org Keywords: prostate cancer, miR-199a-3p, CD44, c-MYC, cancer stem cells Received: May 14, 2016      Accepted: June 13, 2016      Published: July 18, 2016 ABSTRACT Human cancers exhibit significant cellular heterogeneity featuring tumorigenic cancer stem cells (CSCs) in addition to more differentiated progeny with limited tumor-initiating capabilities. Recent studies suggest that microRNAs (miRNAs) regulate CSCs and tumor development. A previous library screening for differential miRNA expression in CD44 + (and other) prostate CSC vs. non-CSC populations identified miR-199a-3p to be among the most highly under-expressed miRNAs in CSCs. In this study, we characterized the biological functions of miR-199a-3p in CD44 + prostate cancer (PCa) cells and in tumor regeneration. Overexpression of miR-199a-3p in purified CD44 + or bulk PCa cells, including primary PCa, inhibited proliferation and clonal expansion without inducing apoptosis. miR-199a-3p overexpression also diminished tumor-initiating capacities of CD44 + PCa cells as well as tumor regeneration from bulk PCa cells. Importantly, inducible miR-199a-3p expression in pre-established prostate tumors in NOD/SCID mice inhibited tumor growth. Using target prediction program and luciferase assays, we show mechanistically that CD44 is a direct functional target of miR-199a-3p in PCa cells. Moreover, miR-199a-3p also directly or indirectly targeted several additional mitogenic molecules, including c-MYC, cyclin D1 (CCND1) and EGFR. Taken together, our results demonstrate how the aberrant loss of a miRNA-mediated mechanism can lead to the expansion and tumorigenic activity of prostate CSCs, further supporting the development and implementation of miRNA mimics for cancer treatment." @default.
• W2493505337 created "2016-08-23" @default.
• W2493505337 creator A5005651786 @default.
• W2493505337 creator A5011391278 @default.
• W2493505337 creator A5019602015 @default.
• W2493505337 creator A5023135578 @default.
• W2493505337 creator A5028462736 @default.
• W2493505337 creator A5037292353 @default.
• W2493505337 creator A5054954914 @default.
• W2493505337 creator A5072493665 @default.
• W2493505337 creator A5078092889 @default.
• W2493505337 creator A5081165104 @default.
• W2493505337 creator A5083990383 @default.
• W2493505337 creator A5087042520 @default.
• W2493505337 date "2016-07-18" @default.
• W2493505337 modified "2023-09-27" @default.
• W2493505337 title "miR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells" @default.
• W2493505337 cites W152867610 @default.
• W2493505337 cites W1555035643 @default.
• W2493505337 cites W1822175513 @default.
• W2493505337 cites W1824707126 @default.
• W2493505337 cites W1901222597 @default.
• W2493505337 cites W1964636114 @default.
• W2493505337 cites W1974254202 @default.
• W2493505337 cites W1992899358 @default.
• W2493505337 cites W2004878973 @default.
• W2493505337 cites W2006247279 @default.
• W2493505337 cites W2014983406 @default.
• W2493505337 cites W2025127622 @default.
• W2493505337 cites W2028945916 @default.
• W2493505337 cites W2046558067 @default.
• W2493505337 cites W2049700579 @default.
• W2493505337 cites W2055393403 @default.
• W2493505337 cites W2056992430 @default.
• W2493505337 cites W2066235353 @default.
• W2493505337 cites W2098388107 @default.
• W2493505337 cites W2100643538 @default.
• W2493505337 cites W2102444665 @default.
• W2493505337 cites W2105504226 @default.
• W2493505337 cites W2105613536 @default.
• W2493505337 cites W2107482095 @default.
• W2493505337 cites W2111840545 @default.
• W2493505337 cites W2118147138 @default.
• W2493505337 cites W2118428599 @default.
• W2493505337 cites W2122147062 @default.
• W2493505337 cites W2136528833 @default.
• W2493505337 cites W2140116051 @default.
• W2493505337 cites W2145387574 @default.
• W2493505337 cites W2145720555 @default.
• W2493505337 cites W2145757445 @default.
• W2493505337 cites W2147200519 @default.
• W2493505337 cites W2148454447 @default.
• W2493505337 cites W2150897565 @default.
• W2493505337 cites W2152627545 @default.
• W2493505337 cites W2152970611 @default.
• W2493505337 cites W2163169932 @default.
• W2493505337 cites W2170685293 @default.
• W2493505337 doi "https://doi.org/10.18632/oncotarget.10652" @default.
• W2493505337 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5302940" @default.
• W2493505337 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27447749" @default.
• W2493505337 hasPublicationYear "2016" @default.
• W2493505337 type Work @default.
• W2493505337 sameAs 2493505337 @default.
• W2493505337 citedByCount "45" @default.
• W2493505337 countsByYear W24935053372016 @default.
• W2493505337 countsByYear W24935053372017 @default.
• W2493505337 countsByYear W24935053372018 @default.
• W2493505337 countsByYear W24935053372019 @default.
• W2493505337 countsByYear W24935053372020 @default.
• W2493505337 countsByYear W24935053372021 @default.
• W2493505337 countsByYear W24935053372022 @default.
• W2493505337 countsByYear W24935053372023 @default.
• W2493505337 crossrefType "journal-article" @default.
• W2493505337 hasAuthorship W2493505337A5005651786 @default.
• W2493505337 hasAuthorship W2493505337A5011391278 @default.
• W2493505337 hasAuthorship W2493505337A5019602015 @default.
• W2493505337 hasAuthorship W2493505337A5023135578 @default.
• W2493505337 hasAuthorship W2493505337A5028462736 @default.
• W2493505337 hasAuthorship W2493505337A5037292353 @default.
• W2493505337 hasAuthorship W2493505337A5054954914 @default.
• W2493505337 hasAuthorship W2493505337A5072493665 @default.
• W2493505337 hasAuthorship W2493505337A5078092889 @default.
• W2493505337 hasAuthorship W2493505337A5081165104 @default.
• W2493505337 hasAuthorship W2493505337A5083990383 @default.
• W2493505337 hasAuthorship W2493505337A5087042520 @default.
• W2493505337 hasBestOaLocation W24935053371 @default.
• W2493505337 hasConcept C104317684 @default.
• W2493505337 hasConcept C121608353 @default.
• W2493505337 hasConcept C126322002 @default.
• W2493505337 hasConcept C143998085 @default.
• W2493505337 hasConcept C145059251 @default.
• W2493505337 hasConcept C1491633281 @default.
• W2493505337 hasConcept C2780192828 @default.
• W2493505337 hasConcept C2780932548 @default.
• W2493505337 hasConcept C28328180 @default.
• W2493505337 hasConcept C41091548 @default.
• W2493505337 hasConcept C502942594 @default.
• W2493505337 hasConcept C54355233 @default.

• next